Anat Ashkenazi - Varian Medical Independent Director
Director
Ms. Anat Ashkenazi serves as Independent Director of the Company., effective December 01, 2018. She had been Senior Vice President, Controller and Chief Financial Officer of Lilly Research Labs and Vice President, Finance and Chief Financial Officer, Lilly Diabetes and Lilly Global Manufacturing and Quality, Chief Financial Officer, Lilly Oncology October 2013April 20. since 2018.
Age | 47 |
Tenure | 6 years |
Phone | 650 493-4000 |
Web | www.varian.com |
Varian Medical Management Efficiency
The company has Return on Asset of 5.92 % which means that on every $100 spent on assets, it made $5.92 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 13.51 %, implying that it generated $13.51 on every 100 dollars invested. Varian Medical's management efficiency ratios could be used to measure how well Varian Medical manages its routine affairs as well as how well it operates its assets and liabilities.The company has 350.5 M in debt with debt to equity (D/E) ratio of 0.16, which may show that the company is not taking advantage of profits from borrowing. Varian Medical Systems has a current ratio of 1.48, which is typical for the industry and considered as normal. Debt can assist Varian Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Varian Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Varian Medical Systems sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Varian to invest in growth at high rates of return. When we think about Varian Medical's use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
William Lacey | Parker Hannifin | 55 | |
Candy Obourn | Parker Hannifin | 69 | |
Timothy Reeves | Emerson Electric | N/A | |
Brenda Freeman | Brp Group | 53 | |
Gloria Flach | Emerson Electric | 61 | |
Kevin Bradicich | The Hanover Insurance | 63 | |
August Busch | Emerson Electric | 76 | |
Joseph Ramrath | The Hanover Insurance | 64 | |
Lori Lee | Emerson Electric | 55 | |
Jillian Evanko | Parker Hannifin | 42 | |
Wing Leung | Highway Holdings Limited | 60 | |
Wenda Millard | Brp Group | 62 | |
W Capps | Brp Group | 66 | |
Daniel Henry | The Hanover Insurance | 70 | |
Martin Hughes | The Hanover Insurance | 71 | |
Lisa Flavin | Brp Group | N/A | |
Kevin Condron | The Hanover Insurance | 72 | |
Brian Geary | Highway Holdings Limited | 56 | |
William Easter | Emerson Electric | 71 | |
Wolfgang Schmitt | Parker Hannifin | 72 | |
Shlomo Tamir | Highway Holdings Limited | 66 |
Management Performance
Return On Equity | 13.51 | |||
Return On Asset | 5.92 |
Varian Medical Systems Leadership Team
Elected by the shareholders, the Varian Medical's board of directors comprises two types of representatives: Varian Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Varian. The board's role is to monitor Varian Medical's management team and ensure that shareholders' interests are well served. Varian Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Varian Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Mark Laret, Independent Director | ||
Regina Dugan, Independent Director | ||
Jose Baselga, Director | ||
Erich Reinhardt, Independent Director | ||
Timothy Guertin, Independent Vice Chairman of the board | ||
Kolleen Kennedy, Executive Vice President, President - Proton Solutions Division and Chief Growth Officer | ||
J Bruff, Chief Financial Officer, Senior Vice President - Finance | ||
Anat Ashkenazi, Independent Director | ||
Susan Bostrom, Independent Director | ||
JeanLuc Butel, Independent Director | ||
Kevin OReilly, Senior Vice President and President Oncology Systems | ||
Sunny Sanyal, Sr. VP and President of Imaging Components Bus.es | ||
Dow Wilson, President, Chief Executive Officer, Director | ||
Francis Facchini, President Interventional Solutions Business | ||
Clarence Verhoef, Senior Vice President - Finance, Corporate Controller | ||
Jeffrey Balser, Independent Director | ||
R Eckert, Independent Chairman of the Board | ||
Venkatraman Thyagarajan, Independent Director | ||
Anshul Maheshwari, Vice President Treasurer, IR Contact Officer | ||
David Illingworth, Independent Director | ||
Judy Bruner, Independent Director | ||
Gary Bischoping, Chief Financial Officer, Senior Vice President - Finance | ||
Juarez Monroeas, Senior Vice President - Human Resources and Chief People Officer | ||
Elisha Finney, CFO and Executive VP of Fin. | ||
John Kuo, Senior Vice President, General Counsel, Corporate Secretary | ||
Rafael Torres, Senior Vice President - Business Development and Strategy | ||
Christopher Toth, President, Chief Executive Officer, Chief Operating Officer | ||
Mike Bruff, Vice president, IR Contact Officer | ||
Michael Hutchinson, Senior Vice President, Chief Legal Officer, Corporate Secretary | ||
Andrew Eckert, Independent Chairman of the Board | ||
Phillip Febbo, Chief Medical Officer, Director | ||
Spencer Sias, Vice President - Corporate Communications and Investor Relations | ||
Chris Toth, President - Varian Oncology Systems | ||
Ruediger NaumannEtienne, Independent Director | ||
Michelle Beau, Independent Director |
Varian Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Varian Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 13.51 | |||
Return On Asset | 5.92 | |||
Profit Margin | 8.90 % | |||
Operating Margin | 16.82 % | |||
Current Valuation | 15.86 B | |||
Shares Outstanding | 91.84 M | |||
Shares Owned By Insiders | 0.29 % | |||
Shares Owned By Institutions | 86.66 % | |||
Number Of Shares Shorted | 2.6 M | |||
Price To Earning | 58.41 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Varian Medical Systems information on this page should be used as a complementary analysis to other Varian Medical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Varian Stock
If you are still planning to invest in Varian Medical Systems check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Varian Medical's history and understand the potential risks before investing.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |